Product Details
| Product Name:
voxelotor |
CAS No.:
1446321-46-5 |
| Purity:
99.87% |
Supply Ability:
10g |
| Release date:
2025/04/28 |
Product Introduction
Bioactivity
| Name | voxelotor |
| Description | Voxelotor (GBT 440) is a novel hemoglobin S (HbS) polymerization inhibitor primarily used for the treatment of sickle cell disease (SCD) and a cytochrome P450 3A4 inhibitor. Voxelotor targets and covalently binds to the N-terminal valine of the HbS alpha chain, thereby stabilizing sickle cell hemoglobin (HbS). |
| In vitro | METHODS: Voxelotor (3-30 µmol/L) was incubated with hemoglobin (25 µmol/L) in TES or saline buffer at 37 ℃ for 45 min, and changes in the binding affinity of O2 for Hb were measured using a TCS hematology analyzer.
RESULTS: Voxelotor, a small molecule that binds to the N-terminal α-chain of Hb, increases the affinity of HbS for oxygen, delays HbS polymerization in vitro and prevents erythrocyte sickling. [1]
METHODS: HepG2 cells were treated with Voxelotor (1 µg/mL) and their metabolites were analyzed by liquid chromatography, high-resolution MS and tandem MS.
RESULTS: Voxelotor can be used for the identification of phase I and phase II metabolites in vitro. [2] |
| In vivo | METHODS: To assess the activity and efficacy of Voxelotor, Voxelotor (100-150 mg/kg, 0.5% methylcellulose/0.5% SDS) was administered by gavage to a mouse model of SCD twice daily for 9-12 days.
RESULTS: Voxelotor reduced isolated sickle cells and prolonged erythrocyte half-life in the SCD mouse model. [1] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 125 mg/mL (370.51 mM), Sonication is recommended.
|
| Keywords | voxelotor | sickle hemoglobin (HbS) | sickle | SCD | polymerization | Inhibitor | inhibit | HbS | haemoglobin | GBT-440 | GBT440 | disease | cell |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pediatric Drug Library | ReFRAME Related Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:188936-12-1
$67.00 / 1mg
-
CAS:864953-39-9
$52.00 / 1mg
-
CAS:52549-17-4
$35.00 / 50mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$0.00/1kg |
VIP2Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-04-01 |
|
|
$35.00/1kg |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-03-28 |
|
|
$6.68/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-08 |
United States